Elemental Biologics
Elemental Biologics

About Elemental

At Elemental Biologics, we apply precision immunology to develop innovative monoclonal antibody (mAb) therapies. Our drug discovery platform combines scientific expertise with advanced technologies to address complex immune-driven diseases.

Elemental Biologics Laboratory

What We Do

We are a biotech company dedicated to the discovery and development of next-generation monoclonal antibody therapies for autoimmune and other inflammatory diseases.

Our innovative approach focuses on addressing multiple disease areas with high unmet medical need, where effective treatment options remain limited.

Learn More

Our Approach

Targeted Discovery

We identify key immune pathways involved in multiple diseases, enabling cross-indication therapies with a single antibody.

Advanced Antibody Engineering

We use state-of-the-art techniques to design and optimize mAbs for maximum precision, potency, and safety.

Translational Development

We advance promising candidates through rigorous preclinical models ensuring strong efficacy and safety, advancing candidates with real-world impact.

Transforming Immune Pathways Into Multi-Disease Solutions

Elemental Biologics creates innovative treatments that target shared immune pathways to address multiple diseases with unmet medical needs, helping more patients while reducing risk and improving development efficiency.

Elemental Biologics Laboratory

Extensive Pipeline of Assets Supported by Strong Data

Our increasingly diversified pipeline includes five advanced programs targeting strategically and commercially viable indications, demonstrating the strength of our preclinical monoclonal antibody discovery and development platform.

Research Focus

Innovative Approaches to Inflammatory Diseases

Our research focuses on developing novel monoclonal antibodies that target specific immune pathways implicated in inflammatory diseases. By precisely targeting these pathways, our therapies aim to provide effective treatment options with fewer side effects than current treatments.

Key areas of interest include:

Autoimmune Disorders
  • Rheumatoid arthritis
  • Multiple sclerosis
Inflammatory Bowel Diseases
  • Crohn's disease
  • Ulcerative colitis
Inflammatory Skin Conditions
  • Psoriasis
  • Atopic dermatitis
Fibrotic Diseases
  • Inflammatory Bowel Disease (IBD) / Intestine Fibrosis
  • Non-Alcoholic Steatohepatitis (NASH) / Liver Fibrosis
  • Idiopathic Pulmonary Fibrosis (IPF) / Lung Fibrosis